{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T22:13:55Z","timestamp":1780352035807,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100017034","name":"Health Technology Assessment international","doi-asserted-by":"publisher","award":["NIHR127325"],"award-info":[{"award-number":["NIHR127325"]}],"id":[{"id":"10.13039\/501100017034","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pre-eclampsia is a multisystem disorder affecting 2.8% of pregnancies in the UK. It usually presents after 20-week gestation with new-onset high blood pressure and proteinuria. Complications include eclampsia, stroke, and HELLP syndrome for the mother and preterm birth, fetal growth restriction, and stillbirth for the baby. Delivery is the only definitive cure, with antenatal care focusing on early detection and management of complications and optimising timing of delivery. Previous studies have shown calcium supplementation may reduce the risk of pre-eclampsia, but findings are driven by large effects seen in small trials that have not been replicated in larger trials. Subgroup analysis suggests benefits may only be seen in women with low dietary calcium intake, so findings may not be applicable to populations with adequate dietary calcium. Although the largest benefits appear to be in high-risk women, data are very limited, with no large trials conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>CaPE is a two-arm parallel triple-blinded, placebo-controlled, multicentre, superiority randomised controlled trial testing the hypothesis that in pregnant women at increased risk, calcium supplementation is effective in reducing the occurrence of pre-eclampsia. The study will recruit 7756 women from approximately 60 obstetric units in hospitals across the UK. Women with a confirmed viable pregnancy, with gestation 22\u2009+\u20090\u00a0weeks or less and deemed eligible for aspirin therapy based on either NICE guideline criteria (at least one high-risk factor or two or more moderate risk factors) or the Fetal Medicine Foundation (FMF) algorithm will be eligible to be randomised in a 1:1 ratio to receive either 2\u00a0g per day of calcium supplementation or placebo taken from 12 to 22\u00a0weeks, up to birth. The primary outcome is clinician diagnosis of pre-eclampsia, based on the ISSHP definition. Key secondary outcomes are severe pre-eclampsia index and preterm birth\u2009&lt;\u200937\u00a0weeks; other secondary outcomes include the Pre-eclampsia Core Outcome Set (COS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Calcium supplementation in high-risk women is an attractive intervention due to its potential efficacy, low cost, and safety profile, but a definitive trial is required to confirm benefits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ISRCTN 12033893. Registered on 25 May 2021.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-026-09513-w","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:39:40Z","timestamp":1773797980000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Calcium supplementation for prevention of pre-eclampsia in high-risk women: study protocol for a randomised triple-blind placebo-controlled trial (CaPE)"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9866-7932","authenticated-orcid":false,"given":"Shireen","family":"Meher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisha","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Brocklehurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Chappell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadil M.","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Hinshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Plachcinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"issue":"6","key":"9513_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/uog.19039","volume":"51","author":"MY Tan","year":"2018","unstructured":"Tan MY, Wright D, Syngelaki A, et al. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound Obstet Gynecol. 2018;51(6):743\u201350.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"9513_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1161\/HYPERTENSIONAHA.117.10803","volume":"72","author":"MA Brown","year":"2018","unstructured":"Brown MA, Magee LA, Kenny LC, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management Recommendations for International Practice. Hypertension. 2018;72:24\u201343.","journal-title":"Hypertension"},{"key":"9513_CR3","unstructured":"DH, editor. Confidential Enquiry into Maternal and Child Health (CEMACH). Perinatal Mortality 2006: England, Wales, and Northern Ireland. London: CEMACH; 2008."},{"issue":"6","key":"9513_CR4","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.ajog.2006.05.021","volume":"195","author":"CV Ananth","year":"2006","unstructured":"Ananth CV, Vintzileos AM. Maternal-fetal conditions necessitating a medical intervention resulting in preterm birth. Am J Obstet Gynecol. 2006;195(6):1557\u201363.","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"9513_CR5","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.3310\/hta12060","volume":"12","author":"CA Meads","year":"2008","unstructured":"Meads CA, Cnossen JS, Meher S, et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess. 2008;12(6):iii\u2013iv, 1-270.","journal-title":"Health Technol Assess"},{"issue":"5728","key":"9513_CR6","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1126\/science.1111726","volume":"308","author":"CW Redman","year":"2005","unstructured":"Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308(5728):1592\u20134.","journal-title":"Science"},{"issue":"10","key":"9513_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004659.pub3","volume":"2019","author":"L Duley","year":"2019","unstructured":"Duley L, Meher S, Hunter KE, Seidler AL, Askie LM. Antiplatelet agents for preventing pre\u2010eclampsia and its complications. Cochrane Database Syst Rev. 2019;(10):CD004659. https:\/\/doi.org\/10.1002\/14651858.CD004659.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"9513_CR8","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1056\/NEJMoa1704559","volume":"377","author":"DL Rolnik","year":"2017","unstructured":"Rolnik DL, Wright D, Poon LC, O\u2019Gorman N, Syngelaki A, de Paco MC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1704559. Epub 2017 Jun 28 PMID: 28657417.","journal-title":"N Engl J Med"},{"issue":"1","key":"9513_CR9","doi-asserted-by":"publisher","first-page":"95.e1","DOI":"10.1016\/j.ajog.2020.07.023","volume":"224","author":"R Hastie","year":"2021","unstructured":"Hastie R, Tong S, Wikstr\u00f6m AK, Sandstr\u00f6m A, Hesselman S, Bergman L. Aspirin use during pregnancy and the risk of bleeding complications: a Swedish population-based cohort study. Am J Obstet Gynecol. 2021;224(1):95.e1-95.e12.","journal-title":"Am J Obstet Gynecol"},{"key":"9513_CR10","unstructured":"Hypertension in pregnancy: diagnosis and management. NICE Guideline. 2019. Available from www.nice.org.uk\/guidance\/ng133. Accessed 08 Dec 2020."},{"issue":"10","key":"9513_CR11","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1093\/ajcn\/33.10.2202","volume":"33","author":"JM Belizan","year":"1980","unstructured":"Belizan JM, Villar J. The relationship between calcium intake and edema-, proteinuria-, and hypertension-getosis: an hypothesis. Am J Clin Nutr. 1980;33(10):2202\u201310.","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"9513_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0020-7292(83)90016-4","volume":"21","author":"J Villar","year":"1983","unstructured":"Villar J, Belizan JM, Fischer PJ. Epidemiologic observations on the relationship between calcium intake and eclampsia. Int J Gynaecol Obstet. 1983;21(4):271\u20138.","journal-title":"Int J Gynaecol Obstet"},{"key":"9513_CR13","first-page":"864","volume":"1","author":"H Rhj","year":"1962","unstructured":"Rhj H. Prevention of pre-eclampsia. Lancet. 1962;1:864\u20135.","journal-title":"Lancet"},{"issue":"1","key":"9513_CR14","first-page":"21","volume":"41","author":"MM Weigel","year":"1991","unstructured":"Weigel MM, Narvaez WM, Lopez A, et al. Prenatal diet, nutrient intake and pregnancy outcome in urban Ecuadorian primiparas. Arch Latinoam Nutr. 1991;41(1):21\u201337.","journal-title":"Arch Latinoam Nutr"},{"issue":"4","key":"9513_CR15","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/0002-9378(88)90091-9","volume":"158","author":"JM Belizan","year":"1988","unstructured":"Belizan JM, Villar J, Repke J. The relationship between calcium intake and pregnancy-induced hypertension: up-to-date evidence. Am J Obstet Gynecol. 1988;158(4):898\u2013902.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"9513_CR16","doi-asserted-by":"publisher","first-page":"45 e1-9.","DOI":"10.1016\/j.ajog.2009.07.037","volume":"202","author":"G Carroli","year":"2010","unstructured":"Carroli G, Merialdi M, Wojdyla D, et al. Effects of calcium supplementation on uteroplacental and fetoplacental blood flow in low-calcium-intake mothers: a randomized controlled trial. Am J Obstet Gynecol. 2010;202(1):45 e1-9.","journal-title":"Am J Obstet Gynecol."},{"issue":"10","key":"9513_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001059.pub5","volume":"2018","author":"GJ Hofmeyr","year":"2018","unstructured":"Hofmeyr GJ, Lawrie TA, Atallah \u00c1N, Torloni MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2018;(10):CD001059. https:\/\/doi.org\/10.1002\/14651858.CD001059.pub5.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"9513_CR18","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/1471-0528.15512","volume":"126","author":"G Cormick","year":"2019","unstructured":"Cormick G, Betr\u00e1n AP, Romero IB, Lombardo CF, G\u00fclmezoglu AM, Ciapponi A, et al. Global inequities in dietary calcium intake during pregnancy: a systematic review and meta-analysis. BJOG. 2019;126(4):444\u201356. https:\/\/doi.org\/10.1111\/1471-0528.15512.","journal-title":"BJOG"},{"issue":"2","key":"9513_CR19","first-page":"136","volume":"28","author":"E De Souza","year":"2006","unstructured":"De Souza E, Sass N. Aspirin and calcium to prevent preeclampsia in chronic hypertensive women with abnormal uterine artery Doppler ultrasound. Rev Bras Ginecol Obstet. 2006;28(2):136.","journal-title":"Rev Bras Ginecol Obstet"},{"issue":"1","key":"9513_CR20","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12916-020-01766-9","volume":"18","author":"KIE Snell","year":"2020","unstructured":"Snell KIE, Allotey J, Smuk M, et al. External validation of prognostic models predicting pre-eclampsia: individual participant data meta-analysis. BMC Med. 2020;18(1):302.","journal-title":"BMC Med"},{"key":"9513_CR21","unstructured":"Fetal Medicine Foundation Algorithm: Risk Assessment for Pre-eclampsia, available from https:\/\/fetalmedicine.org\/research\/assess\/preeclampsia\/first-trimester. Accessed 10 May 2021."},{"key":"9513_CR22","doi-asserted-by":"crossref","unstructured":"Poon LC, Wright D, Thornton S, et al. Mini-combined test compared with NICE guidelines for early risk-assessment for pre-eclampsia: the SPREE diagnostic accuracy study. Southampton (UK): NIHR Journals Library; 2020. PMID: 33226739.","DOI":"10.3310\/eme07080"},{"key":"9513_CR23","unstructured":"BNF: National Institute of Clinical Excellence. Available from: https:\/\/bnf.nice.org.uk\/interaction\/calcium-carbonate-2.html . Accessed 15 May 2018."},{"issue":"3 Pt 1","key":"9513_CR24","first-page":"317","volume":"70","author":"J Villar","year":"1987","unstructured":"Villar J, Repke J, Belizan JM, et al. Calcium supplementation reduces blood pressure during pregnancy: results of a randomized controlled clinical trial. Obstet Gynecol. 1987;70(3 Pt 1):317\u201322.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"9513_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1056\/NEJMoa2307212","volume":"390","author":"P Dwarkanath","year":"2024","unstructured":"Dwarkanath P, Muhihi A, Sudfeld CR, Wylie BJ, Wang M, Perumal N, et al. Two randomized trials of low-dose calcium supplementation in pregnancy. N Engl J Med. 2024;390(2):143\u201353. https:\/\/doi.org\/10.1056\/NEJMoa2307212.","journal-title":"N Engl J Med"},{"key":"9513_CR26","unstructured":"US Department of Health and Human Services. National Institutes of Health, Office of Dietary Supplements. Calcium Fact Sheet for Professionals. Available from: https:\/\/ods.od.nih.gov\/factsheets\/Calcium-HealthProfessional\/. Accessed 3 Jul 2018."},{"issue":"2","key":"9513_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1056\/NEJM199707103370201","volume":"337","author":"RJ Levine","year":"1997","unstructured":"Levine RJ, Hauth JC, Curet LB, Sibai BM, Catalano PM, Morris CD, et al. Trial of calcium to prevent preeclampsia. N Engl J Med. 1997;337(2):69\u201376.","journal-title":"N Engl J Med"},{"key":"9513_CR28","unstructured":"World Health Organization Recommendations for Prevention and Treatment of Pre-eclampsia and Eclampsia. Available from: http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/44703\/9789241548335_eng.pdf;jsessionid=F334CA. Accessed 1 Aug 2018."},{"issue":"9575","key":"9513_CR29","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(07)60712-0","volume":"369","author":"LM Askie","year":"2007","unstructured":"Askie LM, Duley L, Henderson-Smart DJ, et al. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007;369(9575):1791\u20138.","journal-title":"Lancet"},{"key":"9513_CR30","doi-asserted-by":"crossref","unstructured":"Meher S, Walkinshaw S, Neilson J. Risk of pre-eclampsia in women with two moderate risk factors. Archives of Disease in Childhood-Fetal and Neonatal Edition 2011; 96 (Supp 1): Fa102-Fa103.","DOI":"10.1136\/adc.2011.300163.20"},{"issue":"17","key":"9513_CR31","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1001\/jama.2022.4712","volume":"327","author":"KL Tucker","year":"2022","unstructured":"Tucker KL, Mort S, Yu LM, et al. Effect of self-monitoring of blood pressure on diagnosis of hypertension during higher-risk pregnancy. JAMA. 2022;327(17):1656.","journal-title":"JAMA"},{"issue":"6","key":"9513_CR32","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00198-014-2694-5","volume":"25","author":"HM Macdonald","year":"2014","unstructured":"Macdonald HM, Garland A, Burr J, Strachan A, Wood AD, Jamil NA, et al. Validation of a short questionnaire for estimating dietary calcium intakes. Osteoporos Int. 2014;25(6):1765\u201373. https:\/\/doi.org\/10.1007\/s00198-014-2694-5.","journal-title":"Osteoporos Int"},{"key":"9513_CR33","unstructured":"CGEM Calcium Calculator. Available from: https:\/\/webapps.igc.ed.ac.uk\/world\/research\/rheumatological\/calcium-calculator\/."},{"key":"9513_CR34","unstructured":"NICE. NICE health technology evaluations: the manual\u2014economic evaluation. NICE; 2022 [updated 2025 Jul 14; cited 2025 Sep 5]. Available from: https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/economic-evaluation-2"},{"issue":"2","key":"9513_CR35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jval.2015.02.001","volume":"18","author":"SD Ramsey","year":"2015","unstructured":"Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, et al. Cost-effectiveness analysis alongside clinical trials II-an ISPOR good research practices task force report. Value Health. 2015;18(2):161\u201372. https:\/\/doi.org\/10.1016\/j.jval.2015.02.001.","journal-title":"Value Health"},{"issue":"1","key":"9513_CR36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health. 2022;25(1):10\u201331. https:\/\/doi.org\/10.1016\/j.jval.2021.10.008.","journal-title":"Value Health"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09513-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09513-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09513-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T23:16:18Z","timestamp":1777245378000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09513-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9513"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09513-w","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The CaPE trial was approved by the East Midlands Leicester Central REC (REC reference: 21\/EM\/0281, IRAS reference: 262719). Written informed consent to participate is obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"321"}}